Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0006632003
Mon, 20.11.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, November 20, 2023
MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%)
The key secondary [ … ]
Wed, 15.11.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, November 15, 2023
MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
Phase 3 MANIFEST-2 topline results expected by the end of November, with detailed findings in oral presentation at ASH 2023
Monjuvi® U.S. net product sales of US$ 23.4 million (€ 21.5 million) for the third q [ … ]
Thu, 09.11.2023
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, November 09, 2023
Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the third quarter and first nine months 2023 on November 15, 2023, at 10:00 pm CET (09:00 [ … ]
Thu, 02.11.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, November 2, 2023
MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
Following topline results expected in the coming weeks, the oral session at ASH 2023 in December will provide detailed findings from MANIFEST-2
Investor event foc [ … ]
Wed, 25.10.2023
MorphoSys AG
Planegg/Munich, Germany, October 25, 2023
MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
Preliminary Q3 2023 Monjuvi U.S. net product sales of US$ 23.4 million (€ 21.5 million)
Preliminary Gross Margin for Monjuvi U.S. net product sales for Q3 2023 of 65%
Anticipate full y [ … ]
Tue, 12.09.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, September 12, 2023
MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
Tulmimetostat follows pelabresib (2018) and tafasitamab (2014) as the company’s third clinical program to receive Fast Track designation
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced tha [ … ]
Wed, 09.08.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, August 9, 2023
MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results
Monjuvi® U.S. net product sales of US$ 23.6 million (€ 21.7 million) for the second quarter of 2023
Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expec [ … ]
Thu, 03.08.2023
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, August 03, 2023
Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the second quarter and first half 2023 on August 09, 2023, at 10:00 pm CEST (09:00 pm BST; 04:00 pm E [ … ]
Wed, 14.06.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, June 14, 2023
MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will host a virtual investor event on Wednesday, June 21, at 9:00 a.m. EDT / 3:00 p.m. CEST.
During the event, Jean-Paul Kress, M.D., MorphoSys’ Chi [ … ]
Wed, 14.06.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, June 14, 2023
MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will host a virtual investor event on Wednesday, June 21, at 9:00 a.m. EDT / 3:00 p.m. CEST.
During the event, Jean-Paul Kress, M.D., MorphoSys’ Chi [ … ]